Representatives of the drug-distribution sectors argued over the causes of drug prices at a House Energy & Commerce health subcommittee hearing Wednesday (Dec. 13), but lawmakers were left with unanswered questions and the committee Chair Greg Walden (R-OR) said the subcommittee will likely hold another hearing on drug prices early next year. Insulin prices became the example of rising drug prices on which lawmakers based their questions for a segment of the hearing. Walden asked how insulin went from a...